MYC and lymphoma: Notably, a river plot of Eμ-myc lymphoma transcriptomes assigned to best-fit LE prior to therapy compared to their 4-hr CTX-treated matches showed the expected heterogeneity among the LE distributions at baseline, and unveiled a significant dynamic shift of drug-exposed lymphomas towards the TIS-related DC/PU.1 gene signature-enriched LE7 and an emerging LE9 group, hence, convergence towards the best-outcome-associated LE groups (Fig. 6b).